Global Hematologic Malignancies Market Companies

Pharmaceutical
Apr 2025
Global
350 Pages
No of Tables: 220
No of Figures: 60

Buy Now

Request for Sample

Nucleus

Companies Covered

Highest Market Share

Dominant Companies

Other Companies

Global Hematologic Malignancies Market Share Analysis

The data presented is for visualization purposes only and may not reflect actual results.

Nucleus : Company Analysis Platform

Request for Demo >

Frequently Asked Questions

Who are major players in hematologic malignancies market?

Companies such as GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.) and Merck & Co., Inc. (U.S.) are the major companies in the hematologic malignancies market.

What are the recent product launches by major companies in the hematologic malignancies market?

In January 2025, Gilead Sciences announced the commercial launch of its next-generation CAR-T cell therapy, Yescarta (axicabtagene ciloleucel), in the European Union following the receipt of a CE Mark. In September 2024, AbbVie launched its next-generation targeted therapy for chronic lymphocytic leukemia (CLL), Venclexta (venetoclax).

Which countries data is covered in the hematologic malignancies market?

The countries covered in the hematologic malignancies market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.